4 Results for "

solid and haematological malignancies

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "solid and haematological malignancies" in MCE Product Catalog:

Cat. No.: HY-106833
CAS No.: 115621-81-3
SDZ-62-434 free base is a platelet-activating factor (PAF) antagonist. SDZ-62-434 free base has antiproliferative activity in human solid and haematological malignancies .
loading...
    loading...
Cat. No.: HY-106833A
CAS No.: 115621-95-9
SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies .
loading...
    loading...
Cat. No.: HY-W741181
CAS No.: 76155-56-1
Synonyms: Epidoxorubicinol; 4'-Epidoxorubicinol
Target:  

Drug Metabolite

Research Areas:  

Cancer

Epirubicinol is a 13-dihydro metabolite of Epirubicin (HY-13624). Epirubicin has activity similar to Doxorubicin (HY-15142A) in a variety of solid neoplasms and haematologic malignancies .
loading...
    loading...
Cat. No.: HY-182700
CAS No.: 717863-53-1
Target:  

Complement System VEGFR

Research Areas:  

Cancer

NRPa-308 is a potent and orally active Neuropilin-1 (NRP-1) antagonist with an IC50 of 42 μM for inhibiting VEGF-A165 binding to NRP-1. NRPa-308 blocks the specific interaction between VEGF-A165 and NRP-1. NRPa-308 effectively suppresses angiogenesis in vitro and in vivo and reduces the viability of a broad spectrum of human solid and haematological cancer cells. NRPa-308 inhibits tumor growth and prolongs median survival in a human breast cancer xenograft mouse model. NRPa-308 can be used for the research of multiple human malignancies including solid tumors and hematological cancers .
loading...
    loading...